TOLEDO, Ohio, Sept. 5, 2017 /PRNewswire/ -- VentureMed Group, Inc., ("VMG" or the "Company") a medical device company focused on developing and commercializing next-generation endovascular devices to treat peripheral arterial disease (PAD), announced today the appointment of Dave Cox as Vice President of Sales and Marketing. In this role, Mr. Cox will be responsible for all direct sales and distributors worldwide, Dave is currently expanding VMG's North American sales team.
"We are very pleased to have Dave join the team. He brings VMG executive sales leadership and a proven track record for hiring, developing and retaining quality talent, for driving exceptional results," Gary Smith, Chief Executive Officer explains.
Dave was previously Vice President of Sales, Sales Operations and Sales Training for Medtronic's (Covidien and ev3) peripheral sales team, leading both the endo-arterial and endo-venous sales functions. Dave has also served in various management positions of increasing responsibility within the medical device and biotech pharmaceutical industries. He has held progressive leadership roles within these organizations throughout his tenure, including Regional Sales Manager, Area Sales Director and Senior Director of Corporate Accounts. Dave has a solid track record of building high performance teams, successfully integrating sales teams post acquisitions including leading the Covidien peripheral sales function integration in to Medtronic, launching disruptive technologies as well as portfolio expansion products, strategic decision making and driving an elevated level of accountability. Dave has garnered more than 25 years of experience in sales and sales management of highly technical products with the most recent 17 years in the peripheral intervention space.
"I'm very excited to be joining the VMG team. The Flex Scoring Catheter is gaining significant adoption. It is a safe and effective tool for the treatment of diseased femoral and popliteal arteries and native or synthetic arteriovenous (AV) dialysis access fistulae for concomitant angioplasty therapies like the recently FDA approved drug coated balloons." Dave goes on to say, "As a team we are now ready to build out further the VMG commercial strategic plan, expand our sales and commercial support teams, and accelerate market adoption of the Flex Scoring Catheter to help physicians better treat their patients."
Dave holds two bachelor's degrees in Business Administration, in Marketing and Production Management, as well as a minor in Economics, from James Madison University. Additionally, he has completed Executive Education courses in High Impact Sales Strategy; Sales Force Effectiveness; and Sales Force Design at the Northwestern University Kellogg School of Business.
"We are very excited about Dave joining the VMG team and his plans for expanding our commercial efforts," said John Pigott, MD, Founder and Chief Science Officer at VMG. "With his management experience, proven track record and his passion for helping physician's treat patients, Dave will be a fantastic addition to the VMG team and our culture."
About VentureMed Group®
VentureMed Group, Inc. is a commercial-stage medical device company that develops and markets cost-effective interventional instruments to improve the treatment of peripheral artery disease. The Company's innovative product platforms are designed to improve clinical outcomes and reduce procedural costs.
VMG's lead platform is the FLEX Scoring Catheter®. FLEX was designed to treat the complete range of peripheral vessel diameters and lesion lengths and has been described as a safe, efficient and intuitive tool for the treatment of PAD by interventionalists. FLEX is FDA cleared and has CE Mark approval and is available for sale and distribution in the United States and Europe.
VentureMed is located in Toledo, Ohio, USA. For more information, please visit the company's website at www.venturemedgroup.com.
VentureMed Group Media:
VentureMedGroup Investor Relations:
Chief Executive Officer
SOURCE VentureMed Group, Inc.